Haematologica (Oct 2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
- Meletios A. Dimopoulos,
- Katja C. Weisel,
- Kevin W. Song,
- Michel Delforge,
- Lionel Karlin,
- Hartmut Goldschmidt,
- Philippe Moreau,
- Anne Banos,
- Albert Oriol,
- Laurent Garderet,
- Michele Cavo,
- Valentina Ivanova,
- Adrian Alegre,
- Joaquin Martinez-Lopez,
- Christine Chen,
- Andrew Spencer,
- Stefan Knop,
- Nizar J. Bahlis,
- Christoph Renner,
- Xin Yu,
- Kevin Hong,
- Lars Sternas,
- Christian Jacques,
- Mohamed H. Zaki,
- Jesus F. San Miguel
Affiliations
- Meletios A. Dimopoulos
- Alexandra Hospital, Athens, Greece
- Katja C. Weisel
- Hematology & Oncology, Department of Medicine, University Hospital Tübingen, Germany
- Kevin W. Song
- Vancouver General Hospital, Vancouver, BC, Canada
- Michel Delforge
- Department of Hematology, University Hospital Leuven, Belgium
- Lionel Karlin
- Centre Hospitalier Lyon Sud/Hospices Civils de Lyon, Pierre-Bénite, France
- Hartmut Goldschmidt
- University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany
- Philippe Moreau
- Hematology, University Hospital Hôtel-Dieu, Nantes, France
- Anne Banos
- Hematology, Centre Hospitalier de la Côte Basque, Bayonne, France
- Albert Oriol
- Institut Catala d’Oncologia, HGTiP, Barcelona, Spain
- Laurent Garderet
- Hopital Saint Antoine, Paris, France
- Michele Cavo
- Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy
- Valentina Ivanova
- GUZ Moscow City Clinical Hospital S.P. Botkin, Russia
- Adrian Alegre
- Hospital Universitario La Princesa, Madrid, Spain
- Joaquin Martinez-Lopez
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Christine Chen
- Princess Margaret Hospital, Toronto, ON, Canada
- Andrew Spencer
- Alfred Hospital-Monash University, Melbourne, Australia
- Stefan Knop
- University of Würzburg, Germany
- Nizar J. Bahlis
- University of Calgary, AB, Canada
- Christoph Renner
- University Hospital Zurich, Switzerland
- Xin Yu
- Celgene Corporation, Summit, NJ, USA
- Kevin Hong
- Celgene Corporation, Summit, NJ, USA
- Lars Sternas
- Celgene Corporation, Summit, NJ, USA
- Christian Jacques
- Celgene Corporation, Summit, NJ, USA
- Mohamed H. Zaki
- Celgene Corporation, Summit, NJ, USA
- Jesus F. San Miguel
- Clinica Universidad de Navarra, CIMA, Pamplona, Spain
- DOI
- https://doi.org/10.3324/haematol.2014.117077
- Journal volume & issue
-
Vol. 100,
no. 10
Abstract
Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P
